- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: MK-2140 (zilovertamab vedotin)
Total 19 results
-
Merck Sharp & Dohme LLCActive, not recruitingRelapsed or Refractory Diffuse Large B-Cell LymphomaUnited States, China, Poland, Israel, Canada, Chile, Czechia, Estonia, France, Greece, Italy, Korea, Republic of, Norway, Spain, Sweden, Thailand, Turkey
-
Merck Sharp & Dohme LLCRecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation LymphomaPoland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
-
VelosBio Inc., a subsidiary of Merck & Co., Inc...CompletedFollicular Lymphoma | Acute Myeloid Leukemia | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Acute Lymphoid Leukemia | Richter Transformation Lymphoma | Lymphoplasmacytoid Lymphoma | T-cell Non-Hodgkin...United States
-
VelosBio Inc.CompletedGastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditionsUnited States, Canada
-
Merck Sharp & Dohme LLCActive, not recruitingUrothelial CarcinomaAustralia, United States, Chile, Denmark, Israel, Korea, Republic of, Spain
-
Merck Sharp & Dohme LLCRecruitingDiffuse Large B-Cell Lymphoma | DLBCLPoland, United States, France, Israel, Italy, Turkey, Canada, Korea, Republic of, United Kingdom, Thailand, China
-
Merck Sharp & Dohme LLCActive, not recruiting
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCRecruitingLymphoma, Large B-Cell, Diffuse (DLBCL)Italy, Canada, Israel, Korea, Republic of, Poland, Spain, Turkey
-
Kyoto University HospitalMerck Sharp & Dohme LLC; Astellas Pharma Inc; University of Tsukuba; Kobe City... and other collaboratorsRecruiting
-
Merck Sharp & Dohme LLCSeagen Inc.; Astellas Pharma Global Development, Inc.RecruitingUrinary Bladder Cancer, Muscle-invasiveUnited States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, Philippines, Poland, Russian Federation, Singapore, South Africa, Spain, Sweden, Thailand, T... and more
-
Merck Sharp & Dohme LLCAstellas Pharma Inc; Seagen Inc.Active, not recruitingBladder CancerHungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Seagen Inc.Not yet recruitingRenal Pelvis and Ureter Urothelial CarcinomaUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...RecruitingStage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Seagen Inc.WithdrawnBrentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaRecurrent Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Enteropathy-Associated T-Cell Lymphoma | Recurrent Follicular T-Cell Lymphoma | Recurrent Hepatosplenic T-Cell Lymphoma | Recurrent... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
National Cancer Institute (NCI)WithdrawnRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
-
National Cancer Institute (NCI)Active, not recruitingGlioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditionsUnited States, Puerto Rico, Guam